Cosmo NV (LTS:0RGI) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 05, 2026)


LTS:0RGI Cosmo NV LTS:0RGI
79 GF Score
Price CHF69.72
GF Value CHF42.53
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cosmo NV Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cosmo NV's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

LTS:0RGI vs LLY, JNJ, ABBV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, Cosmo NV's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosmo NV Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cosmo NV's Margin of Safety % (DCF Earnings Based) falls into.


LTS:0RGI
79GF Score
Cosmo NV LTS:0RGI
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cosmo NV (LTS:0RGI) Overvalued in 2026?

Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued. The current stock price of CHF69.72 is trading 63.9% above its estimated GF Value™ of CHF42.53. GuruFocus considers Cosmo NV to be Significantly Overvalued.

Key valuation signals for LTS:0RGI:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: CHF42.53 vs. price of CHF69.72 (63.9% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RGI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosmo NV Business Description

Address 91/94 North Wall Quay, 7th Floor, One North Dock, Dublin, IRL, D01 H7V7
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
79GF Score

Get the complete analysis for LTS:0RGI

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF69.72
Price
CHF42.53
GF Value